Phase I Dose Escalation of Gleevec [imatinib] in Combination With RAD001 [everolimus] Plus Hydroxyurea [hydroxycarbamide] for Patients With Recurrent Malignant Glioma

Trial Profile

Phase I Dose Escalation of Gleevec [imatinib] in Combination With RAD001 [everolimus] Plus Hydroxyurea [hydroxycarbamide] for Patients With Recurrent Malignant Glioma

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Feb 2013

At a glance

  • Drugs Everolimus (Primary) ; Imatinib (Primary) ; Hydroxycarbamide
  • Indications Anaplastic astrocytoma; Astrocytoma; Glioblastoma; Glioma
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Nov 2008 Status changed from recruiting to active, no longer recruiting, reported by ClinicalTrials.gov.
    • 25 Feb 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top